The Journal of Endocrinology, Metabolism and Diabetes of South Africa (JEMDSA) is the official journal of SEMDSA (Society for Endocrinology, Metabolism and Diabetes of SA), DESSA (Diabetes Education Society of SA), NOFSA (National Osteoporosis Foundation of SA), SASOM (SA Society of Obesity and Metabolism), LASSA (Lipid and Atherosclerosis Society of SA) and PAEDS-SA (The Paediatric and Adolescent Endocrine and Diabetes Society of SA).

Through stringent peer review, the journal also aims to make a regional contribution to the international knowledge base of endocrinology, metabolism and diabetes and hopes to also offer other African countries the opportunity to make a world-class African contribution.

Readership comprises of the members of the various societies, namely general physicians, endocrinologists, diabetologists, diabetes nurse educators, lipidologists, beriatricians, paediatricians, gynaecologists (specialising in osteoporosis and infertility) and general practitioners with a special interest in endocrinology, metabolism and diabetes.

Jardiance Declared Best International Pharmaceutical Product 2018

Jardiance Declared Best International Pharmaceutical Product 2018 Boehringer Ingelheim’s sodium-glucose co-transporter 2 (SGLT-2) inhibitor, Jardiance (empagliflozin), has been announced winner of the 2018 Prix Galien International Award in the category “Best...

Maternal mortality – Fact Sheet

Maternal mortality - Fact SheetMSD for Mothers     Global statistics1 • Every day, approximately 830 women die from preventable causes related to pregnancy and childbirth. • 99% of all maternal deaths occur in developing countries. • Maternal mortality is...

CIPLA LAUNCHES NEW TRIPLE-COMBINATION ANTIRETROVIRAL DRUG, REYDIN

Ahead of World Aids Day and as part of its continued commitment to ensuring access to quality, affordable antiretrovirals (ARV), Cipla is launching its new triple-combination ARV treatment for HIV in South Africa.

Empagliflozin proven to improve clinical outcomes in real world practice across a broad spectrum of cardiovascular risk

The most recent 2018 treatment recommendations from the American Diabetes Association are that, after considering drug specific and patient factors, treatment for people with atherosclerotic cardiovascular disease (ASCVD) should begin with lifestyle management and metformin and subsequently incorporate an agent proven to reduce major adverse cardiovascular events and/or cardiovascular mortality.

Skin protection range, Dexeryl, receives Allergy Foundation’s seal of approval

Partnership brings established international brand to South African consumers with complementary barrier and cleansing presentations for dry skins.

JEMDSA (July 2016 – June 2017) | 1 782

Wildcard SSL